• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»AI in pathology

Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics

By Pallavi Madhiraju on March 22, 2026   Medical Devices & Diagnostics  

Ibex–HNL Lab Medicine deal signals shift from digital pathology to embedded AI decision support in U.S. diagnostics

Ibex partners with HNL Lab Medicine to deploy AI in prostate cancer diagnostics. Discover what this means for pathology workflows and adoption.

Fulgent Genetics acquires Bako Diagnostics and StrataDx to offset precision diagnostics headwind

By Pallavi Madhiraju on March 19, 2026   Medical Devices & Diagnostics  

Fulgent Genetics acquires Bako Diagnostics and StrataDx to offset precision diagnostics headwind

Fulgent Genetics closes $56.9M Bako and StrataDx acquisition. What it means for anatomic pathology growth, margin risk, and diagnostic consolidation in 2026.

Can Agilent’s new slide scanner system shift digital pathology from pilot to mainstream in Europe?

By Pallavi Madhiraju on January 24, 2026   Medical Devices & Diagnostics  

Can Agilent’s new slide scanner system shift digital pathology from pilot to mainstream in Europe?

Agilent’s new S540MD slide scanner targets scale and AI integration in European pathology labs. Find out what this means for digitisation strategy.

Recent Posts

  • AACR 2026: SAGA Diagnostics pushes Pathlight MRD deeper into metastatic breast and ovarian cancer
  • Agenus AACR 2026 data show immune reprogramming signal in PD-1 refractory gastroesophageal cancer
  • AACR 2026: Can Zai Lab’s zocilurtatug pelitecan change the treatment picture for small cell lung cancer brain metastases?
  • How JANX014 expands Janux Therapeutics’ tumor-activated platform strategy in prostate cancer immunotherapy
  • What Medicus Pharma Ltd.’s SkinJect application signals for Hedgehog pathway-driven cancers
  • Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
  • What Kura Oncology’s latest data reveals about resistance biology in kidney cancer
  • Can Fate Therapeutics, Inc. solve the conditioning chemotherapy problem in CAR T?
  • Could Ampligen become a late-stage pancreatic cancer breakthrough after AIM ImmunoTech’s latest clinical push?
  • What the new J-code means for Glaukos’ Epioxa launch and the future of keratoconus reimbursement
  • Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
  • What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes